GlassScriptPhysician profile
Gregory T Austad
NPI 1558574087
$6,745.70
in general payments reported to CMS, 2019-2025
27 companies · $1,057 in 2025
The $1,057 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $761 · 2020: $720 · 2021: $710 · 2022: $1,136 · 2023: $1,129 · 2024: $1,233 · 2025: $1,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,418.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,866.17 | 2019-2025 | Enbrel, Tavneos, Otezla |
| Abbvie INC. | $1,038.84 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Pfizer INC. | $869.95 | 2019-2025 | |
| Glaxosmithkline, LLC. | $565.44 | 2019-2025 | Benlysta, Nucala |
| Janssen Biotech, INC. | $461.24 | 2019-2025 | Tremfya, Stelara, Remicade |
| Novartis Pharmaceuticals Corporation | $356.52 | 2019-2025 | |
| Ucb, INC. | $298.35 | 2019-2025 | Bimzelx, Cimzia |
| Astrazeneca Pharmaceuticals LP | $246.05 | 2022-2025 | Saphnelo |
| Genentech USA, INC. | $178.27 | 2019-2025 | Actemra, Rituxan |
| Horizon Therapeutics Plc | $143.08 | 2019-2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $136.85 | 2020-2025 | Orencia |
| Organon LLC | $131.38 | 2021-2025 | Hadlima, Renflexis |
| Celgene Corporation | $80.69 | 2019 | |
| Merck Sharp & Dohme LLC | $48.56 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $45.50 | 2023 | Purified Cortrophin Gel |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $43.81 | 2021 | |
| Lilly USA, LLC | $42.24 | 2019-2021 | |
| Fresenius Kabi USA, LLC | $39.35 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.05 | 2024 | Ofev |
| Phadia US INC. | $21.70 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $19.72 | 2024 | Simlandi |
| Sandoz INC. | $18.57 | 2024 | Hyrimoz |
| Regeneron Healthcare Solutions, INC. | $17.36 | 2020 | |
| Aurinia Pharma U.S., INC. | $14.56 | 2024 | Lupkynis |
| Ferring Pharmaceuticals INC. | $12.95 | 2022 | |
| Antares Pharma, INC. | $12.43 | 2019 | |
| Gilead Sciences, INC. | $12.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Austad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.